RET and medullary thyroid gland carcinoma: Similarly, daily oral administration of cabozantinib (140mg) enhanced overall survival (26.6 vs. 21.1 months in treatment vs. placebo group, respectively) and progression-free survival in phase III clinical trial (NCT00704730) for treatment of metastatic MTC cases harboring RET-M918T with an acceptable safety profile (204, 205).